Another new Alzheimer's drug Eli Lilly could debut a new treatment for Alzheimer's disease that targets amyloid, the protein that builds up in the brains of patients.
After approving the first CRISPR treatment, Casgevy, for sickle cell anemia, the FDA is reviewing the same therapy for another genetic blood disorder called beta thalassemia.
[
add
]
[
|
|
...
]